This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus
by Sweta Killa
The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
The Zacks Analyst Blog Highlights URNJ, PFIX, PXE, IHE and XTL
by Zacks Equity Research
URNJ, PFIX, PXE, IHE and XTL are part of the Zacks top Analyst Blog.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
5 Sector ETFs That Outperformed in Turbulent August
by Sweta Killa
Despite the weak fundamentals, a few sectors are still in green, with their ETFs being the top performers.
Inside Tema ETFs' New Oncology ETF (CANC)
by Sanghamitra Saha
Oncology treatment has witnessed remarkable progress due to the relentless efforts of pharmaceutical companies in recent times.
Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts
by Sweta Killa
Let's delve into some of the best ETF charts of Q2 earnings.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
The Zacks Analyst Blog Highlights URNJ, IHE and PXE
by Zacks Equity Research
URNJ, IHE and PXE are part of the Zacks top Analyst Blog.
Pharma ETF (IHE) Hit a 52-Week High
by Sanghamitra Saha
The pharma ETF hit a 52-week high lately. Can it soar higher?
6 Best-Performing ETFs of Last Week
by Sanghamitra Saha
Wall Street delivered a mixed performance last week.
3 Sector ETFs That Beat The Market Last Week
by Sweta Killa
Wall Street wrapped up the last week with mixed performances. The pharma and energy sectors were the biggest winners last week.
Pharma ETFs in Focus Post Q2 Earnings
by Sweta Killa
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
by Sweta Killa
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Pharma ETFs Gain Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.